文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

经许可的 H5N1 疫苗可产生针对高致病性 H5N1 谱系 2.3.4.4b 流感病毒的交叉中和抗体。

Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus.

机构信息

Division of Viral Products, Center for Biologics Evaluation and Research (CBER), US Food and Drug Administration, Silver Spring, MD, USA.

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

出版信息

Nat Med. 2024 Oct;30(10):2771-2776. doi: 10.1038/s41591-024-03189-y. Epub 2024 Jul 16.

DOI:10.1038/s41591-024-03189-y
PMID:39013430
Abstract

The emergence of highly pathogenic avian influenza (HPAI) H5N1 clade 2.3.4.4b viruses and their transmission to dairy cattle and animals, including humans, poses a major global public health threat. Therefore, the development of effective vaccines and therapeutics against H5N1 clade 2.3.4.4b virus is considered a public health priority. In the United States, three H5N1 vaccines derived from earlier strains of HPAI H5N1 (A/Vietnam, clade 1, and A/Indonesia, clade 2.1) virus, with (MF59 or AS03) or without adjuvants, are licensed and stockpiled for pre-pandemic preparedness, but whether they can elicit neutralizing antibodies against circulating H5N1 clade 2.3.4.4b viruses is unknown. In this study, we evaluated the binding, hemagglutination inhibition and neutralizing antibody response generated after vaccination of adults with the three licensed vaccines. Individuals vaccinated with the two adjuvanted licensed H5N1 vaccines generated cross-reactive binding and cross-neutralizing antibodies against the HPAI clade 2.3.4.4b A/Astrakhan/3212/2020 virus. Seroconversion rates of 60-95% against H5 clade 2.3.4.4b were observed after two doses of AS03-adjuvanted-A/Indonesia or three doses of MF59-adjuvanted-A/Vietnam vaccine. These findings suggest that the stockpiled US-licensed adjuvanted H5N1 vaccines generate cross-neutralizing antibodies against circulating HPAI H5N1 clade 2.3.4.4b in humans and may be useful as bridging vaccines until updated H5N1 vaccines become available.

摘要

高致病性禽流感 (HPAI) H5N1 谱系 2.3.4.4b 病毒的出现及其向奶牛和包括人类在内的动物的传播，对全球公共卫生构成了重大威胁。因此，开发针对 H5N1 谱系 2.3.4.4b 病毒的有效疫苗和疗法被认为是公共卫生的当务之急。在美国，三种源自先前高致病性禽流感 H5N1（A/Vietnam，谱系 1 和 A/Indonesia，谱系 2.1）病毒的 H5N1 疫苗，具有（MF59 或 AS03）或不具有佐剂，已获得许可并储备用于大流行前的准备，但它们是否能诱发生殖针对循环 H5N1 谱系 2.3.4.4b 病毒的中和抗体尚不清楚。在这项研究中，我们评估了三种许可疫苗接种成年人后的结合、血凝抑制和中和抗体反应。接种两种佐剂许可 H5N1 疫苗的个体产生了针对 HPAI 谱系 2.3.4.4b 的交叉反应性结合和交叉中和抗体针对 A/Astrakhan/3212/2020 病毒。在接受两剂 AS03 佐剂 A/Indonesia 或三剂 MF59 佐剂 A/Vietnam 疫苗后，观察到对 H5 谱系 2.3.4.4b 的血清转化率为 60-95%。这些发现表明，储备的美国许可的佐剂 H5N1 疫苗可在人类中产生针对循环 HPAI H5N1 谱系 2.3.4.4b 的交叉中和抗体，并且在更新的 H5N1 疫苗可用之前可能有用作为桥梁疫苗。

相似文献

[1]
Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus.

Nat Med. 2024-10

[2]
A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines.

Vaccine. 2017-5-31

[3]
Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.

Virology. 2017-8

[4]
Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.

Vaccine. 2011-12-20

[5]
Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization.

PLoS One. 2014-4-22

[6]
Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

Vaccine. 2009-10-14

[7]
Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults.

BMC Infect Dis. 2014-3-15

[8]
A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults.

BMC Infect Dis. 2010-11-25

[9]
Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.

J Infect Dis. 2010-6-1

[10]
Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge.

PLoS One. 2014-5-21

引用本文的文献

[1]
Assessment of Cross-Reactive Neutralizing Antibodies Induction Against H5N1 Clade 2.3.4.4b by Prior Seasonal Influenza Immunization in Retail Workers.

Open Forum Infect Dis. 2025-8-20

[2]
A clade 2.3.4.4b H5N1 virus vaccine that elicits cross-protective antibodies against conserved domains of H5 and N1 glycoproteins.

bioRxiv. 2025-8-14

[3]
Immunogenicity and safety of a rabies-based highly pathogenic influenza A virus H5 vaccine in cattle.

NPJ Vaccines. 2025-8-19

[4]
AVIAN INFLUENZA VIRUS: THE NEXT PANDEMIC?

Trans Am Clin Climatol Assoc. 2025

[5]
H5N1 Avian Influenza: A Narrative Review of Scientific Advances and Global Policy Challenges.

Viruses. 2025-6-29

[6]
Genotype B3.13 influenza A(H5N1) viruses isolated from dairy cattle demonstrate high virulence in laboratory models, but retain avian virus-like properties.

Nat Commun. 2025-7-23

[7]
Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin-Matrix-M nanoparticle vaccine induces neutralizing responses in nonhuman primates.

Nat Commun. 2025-7-18

[8]
Highly Pathogenic Avian Influenza (H5N1) Clade 2.3.4.4b in Cattle: A Rising One Health Concern.

Animals (Basel). 2025-7-3

[9]
Increase in H5N1 vaccine antibodies confers cross-neutralization of highly pathogenic avian influenza H5N1.

Nat Commun. 2025-7-1

[10]
Production and Immune Response Against Pandemic Influenza Candidate Vaccines as Preparedness Against the Circulating H5N1 Influenza Viruses.

Vaccines (Basel). 2025-6-8

本文引用的文献

[1]
Outbreak of Highly Pathogenic Avian Influenza A(H5N1) Viruses in U.S. Dairy Cattle and Detection of Two Human Cases - United States, 2024.

MMWR Morb Mortal Wkly Rep. 2024-5-30

[2]
Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Virus Infection in Domestic Dairy Cattle and Cats, United States, 2024.

Emerg Infect Dis. 2024-7

[3]
Bird flu outbreak in US cows: why scientists are concerned.

Nature. 2024-4

[4]
Worries about bird flu in U.S. cattle intensify.

Science. 2024-4-5

[5]
H5N1 highly pathogenic avian influenza clade 2.3.4.4b in wild and domestic birds: Introductions into the United States and reassortments, December 2021-April 2022.

Virology. 2023-10

[6]
Haemagglutination inhibition and virus microneutralisation serology assays: use of harmonised protocols and biological standards in seasonal influenza serology testing and their impact on inter-laboratory variation and assay correlation: A FLUCOP collaborative study.

Front Immunol. 2023

[7]
The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination.

NPJ Vaccines. 2022-8-30

[8]
AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization.

NPJ Vaccines. 2018-10-1

[9]
MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.

Sci Transl Med. 2011-6-1

[10]
Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets.

J Virol. 2010-11-17

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索